Attovia grants CFO 140,000 stock options at $17

Attovia Therapeutics, Inc. reported a grant of stock options to its Chief Financial Officer.

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. reported a grant of stock options to its Chief Financial Officer. The grant covers 140,000 Stock Options (Right to Buy) with an exercise price of $17.00 per share, expiring on August 3, 2036, and represents 140,000 options held after the transaction. The options relate to an equivalent number of shares of common stock.

According to the vesting terms, 25% of the options will vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, contingent on continued service to the company.

Insider Trade Summary

Grant/Award: 140,000 shares

Grant/Award 1 txn

Insider Attovia Therapeutics, Inc.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	140,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 140,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

Key Figures

Options granted: 140,000 options Exercise price: $17.00 per share Options after transaction: 140,000 options +3 more

6 metrics

Options granted 140,000 options Stock Option (Right to Buy) granted on 2026-08-04

Exercise price $17.00 per share Conversion or exercise price of the stock options

Options after transaction 140,000 options Total stock options held following the reported grant

Initial vesting date August 4, 2027 25% of the options vest on this date

Remaining vesting period 36 months Remaining 75% vests in equal monthly installments

Option expiration August 3, 2036 Expiration date of the stock options

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price of $17.0000 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of the options shall vest on August 4, 2027 and the remaining options"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-08-03"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award was reported in Attovia Therapeutics (ATTO) latest Form 4?

The filing reports a grant of 140,000 stock options to the Chief Financial Officer. These options have an exercise price of $17.00 per share and are exercisable for 140,000 shares of Attovia Therapeutics common stock.

What is the exercise price of the new stock options at Attovia Therapeutics (ATTO)?

The newly granted stock options carry an exercise price of $17.00 per share. Each option represents the right to buy one share of common stock at this price, subject to the vesting schedule and continued service conditions.

When do the newly granted Attovia Therapeutics (ATTO) options vest?

The options vest over time: 25% vest on August 4, 2027. The remaining 75% vest in equal monthly installments over the subsequent 36 months, provided the officer continues to serve the company during this period.

What is the expiration date of the Attovia Therapeutics (ATTO) stock options reported?

The stock options granted to the Chief Financial Officer expire on August 3, 2036. After this expiration date, any unexercised options will no longer be exercisable for Attovia Therapeutics common stock.

How many Attovia Therapeutics (ATTO) options does the reporting officer hold after this Form 4 transaction?

Following this grant, the reporting officer holds 140,000 stock options as reported. These options are held directly and are subject to the specified vesting schedule and a $17.00 exercise price per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/08/2026 - 02:11 PM Accepted by SEC EDGAR 08/06/2026 - 05:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Attovia Therapeutics, Inc.

(Last) (First) (Middle)

C/O ATTOVIA THERAPEUTICS, INC.

1091 INDUSTRIAL ROAD, SUITE 310

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17	08/04/2026		A		140,000		(1)	08/03/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

	/s/ Steven Chan	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)